期刊文献+

硼替佐米诱导Burkitt淋巴瘤Raji细胞凋亡的研究

Apoptosis of Burkitt's Lymphoma Raji Cell Line Induced by Bortezomib
下载PDF
导出
摘要 本研究探讨硼替佐米对Burkitt淋巴瘤Raji细胞是否具有凋亡诱导作用及其机制。以硼替佐米处理Raji细胞,观察细胞增殖抑制作用的时间效应和剂量效应,在光学显微镜下观察药物作用前后细胞的形态变化,用流式细胞术检测药物孵育前后细胞凋亡率(AP),用RT-PCR法检测药物孵育前后NF-κB和p53基因的表达水平。结果表明,在一定剂量和时间范围内硼替佐米能抑制Raji细胞生长;硼替佐米能诱导Raji细胞凋亡并显示时间和剂量效应;在硼替佐米诱导Raji细胞凋亡过程中,NF-κB及p53基因的表达水平下调。结论:硼替佐米能诱导Raji细胞凋亡,NF-κB基因和p53基因很可能参与了硼替佐米诱导Raji细胞凋亡的调控。 The aim of this study was to clarify whether bortezomib might induce apoptosis in Burkitt's lymphoma Raji cell line and its mechanism. Different concentrations of bortezomib were used to treat Raji cells and its effects of time and dose were observed. Cell morphology was observed under light microscope; flow cytometry was used to analyze cell apoptosis ; RT-PCR was used to detect the expressions of NF-κB and p53 gene mRNAs. The results showed that the bortezomib could inhibit Raji cell growth within a certain range of treating time and dose. Apoptosis were induced in relation to time and dose. The expression of NF-κB mRNA and p53 mRNA decreased after treatment with bortezomib. It is concluded that the bortezomib can induce Raji cell apoptosis, which provides a theoretical basis for clinical treatment. NF-κB and p53 gene are supposed to participate in the bortezomib induced apoptosis of Raji cells.
出处 《中国实验血液学杂志》 CAS CSCD 2009年第3期592-596,共5页 Journal of Experimental Hematology
关键词 硼替佐米 细胞凋亡 NF—κB p53 RAJI细胞 BURKITT淋巴瘤 bortezomib apoptosis NF-κB p53 Raji cell Burkitt lymphoma
  • 相关文献

参考文献18

  • 1Esparis-Ogando A,Alegre A,Aguado B,et al.Bortezomib is an efficient agent in plasma cell leukemias.Int J Callcer,2005,14:666-667 被引量:1
  • 2Musto P,Rossini F,Gay F,et al.Efficacy and safety of bortezomib in patients with plasma cell leukemia.Cancer,2007,109:2286-2289 被引量:1
  • 3Boccadoro M,Morgan G,Cavenagh J.Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy.Cancer Cell Int,2005:5:18-27 被引量:1
  • 4Palombella VJ,Rando OJ,Goldberg AL,et al.The ubiquitinproteasome pathway is required for processing the NF-κB precursor protein and the activation of NF-κB.Cell,1994,78:773-785 被引量:1
  • 5Mitsiades N,Mitsiades CS,Richardson PG,et al.The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agent:therapeutic applications.Blood,2003,101:2377-2379 被引量:1
  • 6Adams J,Palombella VJ,Elliott PJ.Proteasome inhibition:a new strategy in cancer treatment.Invest New Drugs,2000,18:109-121 被引量:1
  • 7Voorhees PM,Dees EC,O'Neil B,et al.The proteasome as a target for cancer therapy.Clin Cancer Res,2003,9:6317-6324 被引量:1
  • 8An WG,Hwang SG,Trepel JB,et al.Protease inhibitor-induced apoptosis:accumulation of wt p53,p21 WAF1/CIP1,and induction of apoptosis are independent markers of proteasome inhibition.Leukemia,2000,14:1276-1283 被引量:1
  • 9Sen R,Baltimore D.Multiple nuclear factors interact with the immunoglobulin enhancer sequences.Cell,1986,46:705-716 被引量:1
  • 10Oltval ZN,Milliman CL,Korsmeyer SJ.Bcl-2 hetetodimerizes in vivo with a conserved homolog,Bax,that accelerates programmed cell death.Cell,1993,74:609-619 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部